Evaluation of a workplace HIV treatment programme in South Africa

AIDS

Volumn 21, Issue SUPPL. 3, 2007, Pages

  Charalambous, Salome ^a   Innes, Craig ^a   Muirhead, Debbie ^a,b   Kumaranayake, Lilani ^b   Fielding, Katherine ^b   Pemba, Lindiwe ^a   Hamilton, Robin ^a   Grant, Alison ^b   Churchyard, Gavin J ^a,b,c  

^a AURUM INSTITUTE   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Antiretroviral therapy; Cohort; HIV; Industrial; Programmes; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEATH; DEVELOPED COUNTRY; EMPLOYMENT; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOUTH AFRICA; TREATMENT OUTCOME; VIRUS LOAD; WORKPLACE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL HEALTH SERVICES; SOUTH AFRICA; TREATMENT OUTCOME; WORKPLACE;

EID: 34547660099     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279696.63438.aa     Document Type: Review

References (26)

1. World Health Organisation. South Africa unveils national HIV/ AIDS treatment programme. Bull WHO 2004; 8, January 2004. Available at: http//:www.scielosp.org/pdf/bwho/v82n1/ v82n1a19.pdf. Accessed: April 2007.
2. World Health Organisation. HIV/AIDS epidemiological surveillance report for the WHO African region 2005 update. Geneva: WHO; 2005.
3. South African Department of Health. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. 19 November 2003. Available at: www.doh. gov.za. Accessed: April 2007.
4. World Health Organisation. The 3 by 5 initiative. 2003. Available at: http//:www.who.int/3by5/en. Accessed: 30 May 2004.
5. International Treatment Preparedness Coalition (ITPC). Missing the target. A report on HIV/AIDS treatment access from the frontlines. AIDS Law Project, Cape Town, South Africa 28 November 2005.
6. World Economic Forum. A Global Review of the Business Response to HIV/AIDS, 2004-2005, January 2005, Available at: https://www.weforum.org/pdf/ Initiatives/GHI_Report_2005_ Abridged.pdf Accessed May 2007.
7. Plumley B, Bery P, Dadd C. Discussion paper: beyond the workplace: business participation in the multi-sectoral response to HIV/AIDS. In: XIVth International Conference on AIDS. Barcelona, Spain, 7-12 July 2002. Abstract number-ThOrG1503.
8. Auvert B, Males S, Puren A, Taljaard D, Carael M, Williams B. Can highly active antiretroviral therapy reduce the spread of HIV?: a study in a township of South Africa. J Acquir Immune Defic Syndr 2004; 36:613-621.
9. Wall Street Journal, New York, USA. Giant Anglo American will supply free Anti-AIDS drugs to African workers, 7 August 2002.
10. Charalambous S, Grant AD, Day JH, Chaisson RE, Hayes RE, Churchyard GJ. Feasibility and acceptability of a specialist clinical service for HIV-infected mineworkers in South Africa. AIDS Care 2004; 6:47-56.
11. Harries AD, Gomani P, Teck R, de Teck OA, Bakali E, Zachariah R, et al. Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. Trans R Soc Trop Med Hyg 2004; 98:695-701.
12. Libamba E, Makombe S, Mhango E, de Ascurra Teck O, Limbambala E, Schouten EJ, Harries AD. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. Bull WHO 2006; 84:320-326.
13. Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007; 19:34-41.
14. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 2002; 360:34-40.
15. Laurent C, Diakhate N, Gueye NFD, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
16. Severe P, Leger P, Macarthur C, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325-2334.
17. Moore R, Keruly JC, Gebo KA, Lucas GM. Improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005; 39:195-198.
18. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
19. Badri M, Maartens G, Mandalia S, Bekker LG, Perrod JR, Platt RW, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PloS Med 2006; 3:e4.
20. Boulle A, Kenyon C, Skordis J, Wood R. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. S Afr Med J 2002; 92:811-817.
21. Charalambous S, Stenson A, Fielding KL, Pemba L, Churchyard GJ, Grant AD. 6-Month outcomes among HIV-infected individuals starting antiretroviral therapy in South Africa. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil, 24-27 July 2005 [Abstract MoPe11.2C41].
22. Charalambous S, Fielding K, Stenson A, Pemba L, Innes C, Senoge S, et al. 12-Month outcomes among HIV-infected individuals starting antiretroviral therapy in South Africa. In: XVIth International AIDS Conference. Toronto, Canada, 13-17 August 2006 [Abstract WEPE0123].
23. Grant AD, Fielding KL, Charalambous S, Stenson A, Whetham J, Puso T, et al. Risk factors for early mortality among HIVinfected individuals starting antiretroviral therapy in South Africa. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil, 24-27 July 2005 [Abstract MoPe11.6C25].
24. Dahab M, Hamilton R, Charalambous S, Dube N, Tsimele J, Govender N, et al. A quantitative study of barriers & facilitators to adherence in an antiretroviral therapy programme in South Africa. In: XVIth International AIDS Conference. Toronto, Canada, 13-17 August 2006 [Abstract TUPE0151].
25. Muirhead D, Kumaranayake L, Pozo-Martin F, Charalambous S, Pemba L, Grant A, et al. Early savings resulting from employer-sponsored ART in a large South African workforce setting. In: 2nd South African AIDS Conference. Durban, South Africa, 7-10 June 2005 [Abstract 652, oral presentation].
26. Churchyard GJ, Fielding KL, Charalambous S, Whetham J, Pemba L, Day J, Grant AD. Antiretroviral therapy reduces risk of TB among Southern African gold miners. In: XVIth International AIDS Conference. Toronto, Canada, 13-17 August 2006 [Abstract MOPE0172].